난포자극호르몬 시장 : 유형별, 용도별, 최종사용자별 - 세계 기회 분석과 산업 예측(2024-2033년)

Follicle Stimulating Hormone Market By Type , By Application By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033

US $ 4,425 ￦ 6,127,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 7,412 ￦ 10,264,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

난포자극호르몬 시장

난포자극호르몬 시장은 2023년에는 19억 4,000만 달러로 평가되며, 2024-2035년 CAGR은 5.7%를 보이며, 2035년에는 37억 4,000만 달러에 달할 것으로 추정됩니다.

난포자극호르몬(FSH)은 뇌하수체에서 생산되는 중요한 호르몬으로 생식 건강에 중요한 역할을 합니다. 여성의 경우, FSH는 난자를 포함한 난포의 발달을 자극하므로 특히 생리주기와 난소 기능에 관여하며, 생리주기와 임신에 관여하는 두 가지 필수 호르몬인 에스트로겐과 프로게스테론의 생성을 조절합니다. 남성의 경우, 이 호르몬은 고환에서 정자 세포의 생산을 자극합니다. 황체형성호르몬(LH)과 함께 생식 능력과 정상적인 생식 기능을 조절하는 역할을 합니다. 생식 기능과 함께 FSH는 뼈 건강에도 영향을 미치며, 다낭성난소증후군(PCOS) 및 불임과 같은 증상에도 필수적입니다.

불임의 유병률 증가와 FSH 기반 약물의 이점에 대한 개인의 인식 증가는 난포자극호르몬 시장의 성장을 가속하는 주요 요인입니다. 또한 보조생식술(ART)의 채택이 증가함에 따라 시장 성장을 크게 증가시킬 것으로 예상됩니다. 현재 자궁내막 줄기세포의 여러 재생 관련 기능에서 FSH의 탐색이 견인력을 얻고 있습니다. 과학자들에 따르면 이는 여성의 임신율을 증가시킬 것으로 예상됩니다.

그러나 FSH 요법을 포함한 불임 치료 관련은 일부 지역에서는 보험이 적용되지 않습니다. 이 때문에 이러한 치료는 고가이며, 그 결과 이러한 치료를 받을 수 없어 시장 개척을 억제하고 있습니다. 또한 FSH 투여로 인한 부작용은 다태임신, 난소과자극증후군(OHSS), 호르몬 불균형 등 심각한 부작용을 초래할 수 있습니다. 이 때문에 FSF의 사용은 제한적이며, 시장 관계자들에게는 도전과제가 되고 있습니다. 반대로 생활습관의 변화와 환경적 스트레스 요인으로 인해 전 세계에서 불임의 비율이 급증하고 있습니다. 질병통제예방센터(CDC)의 2023년 논문에 따르면 15-49세 여성의 13.4%가 불임에 시달리고 있는 것으로 보고되었습니다. 이러한 통계는 이 시장의 미래가 유망하다는 것을 보여줍니다.

부문 개요

난포자극호르몬 시장은 유형, 용도, 최종사용자, 지역으로 분류됩니다. 유형별로 시장은 재조합 FSH와 소변내 FSH로 나뉩니다. 용도별로는 불임 치료와 보조 생식 의학으로 분류됩니다. 최종사용자에 따라 병원, 불임 클리닉, 냉동 은행으로 분류됩니다. 지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 분석됩니다.

주요 조사 결과

유형별로는 재조합 FSH 부문이 2023년 시장을 장악했습니다.

용도별로는 불임 치료 부문이 2023년 높은 시장 점유율을 차지했습니다.

지역별로는 북미가 2023년 가장 높은 매출을 올릴 것으로 예상됩니다.

이 보고서에서 가능한 커스터마이징(추가 비용 및 일정이 있습니다.)

• 제품별/부문별 진입기업 시장 점유율 분석
• 국가별 또는 지역별 추가 분석 - 시장 규모 및 전망
• 평균 판매가격 분석/가격대 분석
• 기업 개요 확대 리스트
• 과거 시장 데이터

목차

제1장 서론

제2장 개요

제3장 시장 구도

• 시장의 정의와 범위
• 주요 조사 결과
  • 주요 투자 기회
  • 주요 성공 전략
• Porter's Five Forces 분석
• 시장 역학
  • 촉진요인
  • 억제요인
  • 기회

제4장 난포자극호르몬 시장 : 유형별

• 시장 개요
• 유전자재조합 FSH
• 뇨중 FSH

제5장 난포자극호르몬 시장 : 용도별

• 시장 개요
• 불임 치료
• 생식 보조 의료

제6장 난포자극호르몬 시장 : 최종사용자별

• 시장 개요
• 병원
• 불임 치료 클리닉
• 크라이오뱅크

제7장 난포자극호르몬 시장 : 지역별

• 시장 개요
• 북미
  • 주요 시장 동향과 기회
  • 미국의 난포자극호르몬 시장
  • 캐나다의 난포자극호르몬 시장
  • 멕시코의 난포자극호르몬 시장
• 유럽
  • 주요 시장 동향과 기회
  • 독일의 난포자극호르몬 시장
  • 프랑스의 난포자극호르몬 시장
  • 영국의 난포자극호르몬 시장
  • 이탈리아의 난포자극호르몬 시장
  • 스페인의 난포자극호르몬 시장
  • 기타 유럽의 난포자극호르몬 시장
• 아시아태평양
  • 주요 시장 동향과 기회
  • 일본의 난포자극호르몬 시장
  • 중국의 난포자극호르몬 시장
  • 호주의 난포자극호르몬 시장
  • 인도의 난포자극호르몬 시장
  • 한국의 난포자극호르몬 시장
  • 기타 아시아태평양의 난포자극호르몬 시장
• 라틴아메리카·중동 및 아프리카
  • 주요 시장 동향과 기회
  • 브라질의 난포자극호르몬 시장
  • 사우디아라비아의 난포자극호르몬 시장
  • 남아프리카공화국의 난포자극호르몬 시장
  • 기타 라틴아메리카·중동 및 아프리카의 난포자극호르몬 시장

제8장 경쟁 구도

• 서론
• 주요 성공 전략
• 주요 10 기업의 제품 지도제작
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2023년)

제9장 기업 개요

• Pfizer Inc.
• Novartis AG
• Abbott Laboratories
• Sanofi S.A.
• Boehringer Ingelheim GmbH
• Merck KGaA
• Teva Pharmaceutical Industries Ltd.
• Intas Pharmaceuticals Ltd.
• Cipla Ltd.
• Zydus Lifesciences Limited

KSA

영문 목차

영문목차

Follicle Stimulating Hormone Market

The follicle stimulating hormone market was valued at $1.94 billion in 2023 and is estimated to reach $3.74 billion by 2035, exhibiting a CAGR of 5.7% from 2024 to 2035.

Follicle stimulating hormone (FSH) is a vital hormone produced by the pituitary gland that plays a key role in reproductive health. In females, FSH is specifically involved in the menstrual cycle and ovarian function as it stimulates the development of ovarian follicles containing the ovum. FSH further regulates the production of two essential hormones involved in menstrual cycle and pregnancy that are estrogen and progesterone. In males, the hormone stimulates sperm cells production in the testes. It works alongside luteinizing hormone (LH) to regulate fertility and normal reproductive functions. Along with its reproductive functions, FSH impacts the bone health and is essential in conditions such as polycystic ovary syndrome (PCOS) and infertility.

Increase in prevalence of infertility and rise in awareness among individuals regarding the benefits of FSH-based medications are the key factors driving the growth of the follicle stimulating hormone market. Moreover, increase in adoption of assisted reproductive technology (ART) is expected to significantly augment the growth of the market. Currently, the exploration of FSH in several regeneration-related functions of endometrial stem cells is acquiring traction. According to scientists, this is predicted to subsequently increase pregnancy rates among females.

However, fertility-related treatments, including FSH therapies, are not covered under insurance policies in several regions. This makes such treatments expensive for several individuals, thus preventing them from undergoing such treatments and restraining the market development. Moreover, the side-effects of FSH administration are severe in some cases, including multiple pregnancies, ovarian hyperstimulation syndrome (OHSS), and hormonal imbalances. This limits the utilization of FSF and presents challenges for the market players. On the contrary, infertility rates are surging globally owing to lifestyle changes and environmental stressors. As per a 2023 article by Center of Disease Control and Prevention, 13.4% of women between the age 15-49 were reported to suffer from impaired fecundity. These statistics indicate a promising future for the market.

Segment Overview

The follicle stimulating hormone market is segmented into type, application, end user, and region. On the basis of type, the market is bifurcated into recombinant FSH and urinary FSH. By application, it is classified into infertility treatment and assisted reproductive technology. As per end user, it is categorized into hospitals, fertility clinics, and cryobanks. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of type, the recombinant FSH segment dominated the market in 2023.

By application, the infertility treatment segment acquired a high market share in 2023.

Region wise, North America was the highest revenue generator in 2023.

Competition Analysis

The major players operating in the follicle stimulating hormone market are Pfizer Inc., Novartis AG, Abbott Laboratories, Sanofi S.A., Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd., Merck Specialities Pvt Ltd., Intas Pharmaceuticals Ltd., and Cipla Ltd. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Market share analysis of players by products/segments
• Additional country or region analysis- market size and forecast
• Average Selling Price Analysis / Price Point Analysis
• Expanded list for Company Profiles
• Historic market data

Key Market Segments

By Type

• Recombinant FSH
• Urinary FSH

By Application

• Infertility Treatment
• Assisted Reproductive Technology

By End User

• Hospitals
• Fertility Clinics
• Cryobanks

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Pfizer Inc.
• Novartis AG
• Abbott Laboratories
• Sanofi S.A.
• Boehringer Ingelheim GmbH
• Merck KGaA
• Teva Pharmaceutical Industries Ltd.
• Intas Pharmaceuticals Ltd.
• Cipla Ltd.
• Zydus Lifesciences Limited

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report Description
• 1.2. Key Market Segments
• 1.3. Key Benefits
• 1.4. Research Methodology
  • 1.4.1. Primary Research
  • 1.4.2. Secondary Research
  • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

• 3.1. Market Definition and Scope
• 3.2. Key Findings
  • 3.2.1. Top Investment Pockets
  • 3.2.2. Top Winning Strategies
• 3.3. Porter's Five Forces Analysis
  • 3.3.1. Bargaining Power of Suppliers
  • 3.3.2. Threat of New Entrants
  • 3.3.3. Threat of Substitutes
  • 3.3.4. Competitive Rivalry
  • 3.3.5. Bargaining Power among Buyers
• 3.4. Market Dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: FOLLICLE STIMULATING HORMONE MARKET, BY TYPE

• 4.1. Market Overview
  • 4.1.1 Market Size and Forecast, By Type
• 4.2. Recombinant FSH
  • 4.2.1. Key Market Trends, Growth Factors and Opportunities
  • 4.2.2. Market Size and Forecast, By Region
  • 4.2.3. Market Share Analysis, By Country
• 4.3. Urinary FSH
  • 4.3.1. Key Market Trends, Growth Factors and Opportunities
  • 4.3.2. Market Size and Forecast, By Region
  • 4.3.3. Market Share Analysis, By Country

CHAPTER 5: FOLLICLE STIMULATING HORMONE MARKET, BY APPLICATION

• 5.1. Market Overview
  • 5.1.1 Market Size and Forecast, By Application
• 5.2. Infertility Treatment
  • 5.2.1. Key Market Trends, Growth Factors and Opportunities
  • 5.2.2. Market Size and Forecast, By Region
  • 5.2.3. Market Share Analysis, By Country
• 5.3. Assisted Reproductive Technology
  • 5.3.1. Key Market Trends, Growth Factors and Opportunities
  • 5.3.2. Market Size and Forecast, By Region
  • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: FOLLICLE STIMULATING HORMONE MARKET, BY END USER

• 6.1. Market Overview
  • 6.1.1 Market Size and Forecast, By End User
• 6.2. Hospitals
  • 6.2.1. Key Market Trends, Growth Factors and Opportunities
  • 6.2.2. Market Size and Forecast, By Region
  • 6.2.3. Market Share Analysis, By Country
• 6.3. Fertility Clinics
  • 6.3.1. Key Market Trends, Growth Factors and Opportunities
  • 6.3.2. Market Size and Forecast, By Region
  • 6.3.3. Market Share Analysis, By Country
• 6.4. Cryobanks
  • 6.4.1. Key Market Trends, Growth Factors and Opportunities
  • 6.4.2. Market Size and Forecast, By Region
  • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: FOLLICLE STIMULATING HORMONE MARKET, BY REGION

• 7.1. Market Overview
  • 7.1.1 Market Size and Forecast, By Region
• 7.2. North America
  • 7.2.1. Key Market Trends and Opportunities
  • 7.2.2. Market Size and Forecast, By Type
  • 7.2.3. Market Size and Forecast, By Application
  • 7.2.4. Market Size and Forecast, By End User
  • 7.2.5. Market Size and Forecast, By Country
  • 7.2.6. U.S. Follicle Stimulating Hormone Market
    • 7.2.6.1. Market Size and Forecast, By Type
    • 7.2.6.2. Market Size and Forecast, By Application
    • 7.2.6.3. Market Size and Forecast, By End User
  • 7.2.7. Canada Follicle Stimulating Hormone Market
    • 7.2.7.1. Market Size and Forecast, By Type
    • 7.2.7.2. Market Size and Forecast, By Application
    • 7.2.7.3. Market Size and Forecast, By End User
  • 7.2.8. Mexico Follicle Stimulating Hormone Market
    • 7.2.8.1. Market Size and Forecast, By Type
    • 7.2.8.2. Market Size and Forecast, By Application
    • 7.2.8.3. Market Size and Forecast, By End User
• 7.3. Europe
  • 7.3.1. Key Market Trends and Opportunities
  • 7.3.2. Market Size and Forecast, By Type
  • 7.3.3. Market Size and Forecast, By Application
  • 7.3.4. Market Size and Forecast, By End User
  • 7.3.5. Market Size and Forecast, By Country
  • 7.3.6. Germany Follicle Stimulating Hormone Market
    • 7.3.6.1. Market Size and Forecast, By Type
    • 7.3.6.2. Market Size and Forecast, By Application
    • 7.3.6.3. Market Size and Forecast, By End User
  • 7.3.7. France Follicle Stimulating Hormone Market
    • 7.3.7.1. Market Size and Forecast, By Type
    • 7.3.7.2. Market Size and Forecast, By Application
    • 7.3.7.3. Market Size and Forecast, By End User
  • 7.3.8. UK Follicle Stimulating Hormone Market
    • 7.3.8.1. Market Size and Forecast, By Type
    • 7.3.8.2. Market Size and Forecast, By Application
    • 7.3.8.3. Market Size and Forecast, By End User
  • 7.3.9. Italy Follicle Stimulating Hormone Market
    • 7.3.9.1. Market Size and Forecast, By Type
    • 7.3.9.2. Market Size and Forecast, By Application
    • 7.3.9.3. Market Size and Forecast, By End User
  • 7.3.10. Spain Follicle Stimulating Hormone Market
    • 7.3.10.1. Market Size and Forecast, By Type
    • 7.3.10.2. Market Size and Forecast, By Application
    • 7.3.10.3. Market Size and Forecast, By End User
  • 7.3.11. Rest of Europe Follicle Stimulating Hormone Market
    • 7.3.11.1. Market Size and Forecast, By Type
    • 7.3.11.2. Market Size and Forecast, By Application
    • 7.3.11.3. Market Size and Forecast, By End User
• 7.4. Asia-Pacific
  • 7.4.1. Key Market Trends and Opportunities
  • 7.4.2. Market Size and Forecast, By Type
  • 7.4.3. Market Size and Forecast, By Application
  • 7.4.4. Market Size and Forecast, By End User
  • 7.4.5. Market Size and Forecast, By Country
  • 7.4.6. Japan Follicle Stimulating Hormone Market
    • 7.4.6.1. Market Size and Forecast, By Type
    • 7.4.6.2. Market Size and Forecast, By Application
    • 7.4.6.3. Market Size and Forecast, By End User
  • 7.4.7. China Follicle Stimulating Hormone Market
    • 7.4.7.1. Market Size and Forecast, By Type
    • 7.4.7.2. Market Size and Forecast, By Application
    • 7.4.7.3. Market Size and Forecast, By End User
  • 7.4.8. Australia Follicle Stimulating Hormone Market
    • 7.4.8.1. Market Size and Forecast, By Type
    • 7.4.8.2. Market Size and Forecast, By Application
    • 7.4.8.3. Market Size and Forecast, By End User
  • 7.4.9. India Follicle Stimulating Hormone Market
    • 7.4.9.1. Market Size and Forecast, By Type
    • 7.4.9.2. Market Size and Forecast, By Application
    • 7.4.9.3. Market Size and Forecast, By End User
  • 7.4.10. South Korea Follicle Stimulating Hormone Market
    • 7.4.10.1. Market Size and Forecast, By Type
    • 7.4.10.2. Market Size and Forecast, By Application
    • 7.4.10.3. Market Size and Forecast, By End User
  • 7.4.11. Rest of Asia-Pacific Follicle Stimulating Hormone Market
    • 7.4.11.1. Market Size and Forecast, By Type
    • 7.4.11.2. Market Size and Forecast, By Application
    • 7.4.11.3. Market Size and Forecast, By End User
• 7.5. LAMEA
  • 7.5.1. Key Market Trends and Opportunities
  • 7.5.2. Market Size and Forecast, By Type
  • 7.5.3. Market Size and Forecast, By Application
  • 7.5.4. Market Size and Forecast, By End User
  • 7.5.5. Market Size and Forecast, By Country
  • 7.5.6. Brazil Follicle Stimulating Hormone Market
    • 7.5.6.1. Market Size and Forecast, By Type
    • 7.5.6.2. Market Size and Forecast, By Application
    • 7.5.6.3. Market Size and Forecast, By End User
  • 7.5.7. Saudi Arabia Follicle Stimulating Hormone Market
    • 7.5.7.1. Market Size and Forecast, By Type
    • 7.5.7.2. Market Size and Forecast, By Application
    • 7.5.7.3. Market Size and Forecast, By End User
  • 7.5.8. South Africa Follicle Stimulating Hormone Market
    • 7.5.8.1. Market Size and Forecast, By Type
    • 7.5.8.2. Market Size and Forecast, By Application
    • 7.5.8.3. Market Size and Forecast, By End User
  • 7.5.9. Rest of LAMEA Follicle Stimulating Hormone Market
    • 7.5.9.1. Market Size and Forecast, By Type
    • 7.5.9.2. Market Size and Forecast, By Application
    • 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top Winning Strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

• 9.1. Pfizer Inc.
  • 9.1.1. Company Overview
  • 9.1.2. Key Executives
  • 9.1.3. Company Snapshot
  • 9.1.4. Operating Business Segments
  • 9.1.5. Product Portfolio
  • 9.1.6. Business Performance
  • 9.1.7. Key Strategic Moves and Developments
• 9.2. Novartis AG
  • 9.2.1. Company Overview
  • 9.2.2. Key Executives
  • 9.2.3. Company Snapshot
  • 9.2.4. Operating Business Segments
  • 9.2.5. Product Portfolio
  • 9.2.6. Business Performance
  • 9.2.7. Key Strategic Moves and Developments
• 9.3. Abbott Laboratories
  • 9.3.1. Company Overview
  • 9.3.2. Key Executives
  • 9.3.3. Company Snapshot
  • 9.3.4. Operating Business Segments
  • 9.3.5. Product Portfolio
  • 9.3.6. Business Performance
  • 9.3.7. Key Strategic Moves and Developments
• 9.4. Sanofi S.A.
  • 9.4.1. Company Overview
  • 9.4.2. Key Executives
  • 9.4.3. Company Snapshot
  • 9.4.4. Operating Business Segments
  • 9.4.5. Product Portfolio
  • 9.4.6. Business Performance
  • 9.4.7. Key Strategic Moves and Developments
• 9.5. Boehringer Ingelheim GmbH
  • 9.5.1. Company Overview
  • 9.5.2. Key Executives
  • 9.5.3. Company Snapshot
  • 9.5.4. Operating Business Segments
  • 9.5.5. Product Portfolio
  • 9.5.6. Business Performance
  • 9.5.7. Key Strategic Moves and Developments
• 9.6. Merck KGaA
  • 9.6.1. Company Overview
  • 9.6.2. Key Executives
  • 9.6.3. Company Snapshot
  • 9.6.4. Operating Business Segments
  • 9.6.5. Product Portfolio
  • 9.6.6. Business Performance
  • 9.6.7. Key Strategic Moves and Developments
• 9.7. Teva Pharmaceutical Industries Ltd.
  • 9.7.1. Company Overview
  • 9.7.2. Key Executives
  • 9.7.3. Company Snapshot
  • 9.7.4. Operating Business Segments
  • 9.7.5. Product Portfolio
  • 9.7.6. Business Performance
  • 9.7.7. Key Strategic Moves and Developments
• 9.8. Intas Pharmaceuticals Ltd.
  • 9.8.1. Company Overview
  • 9.8.2. Key Executives
  • 9.8.3. Company Snapshot
  • 9.8.4. Operating Business Segments
  • 9.8.5. Product Portfolio
  • 9.8.6. Business Performance
  • 9.8.7. Key Strategic Moves and Developments
• 9.9. Cipla Ltd.
  • 9.9.1. Company Overview
  • 9.9.2. Key Executives
  • 9.9.3. Company Snapshot
  • 9.9.4. Operating Business Segments
  • 9.9.5. Product Portfolio
  • 9.9.6. Business Performance
  • 9.9.7. Key Strategic Moves and Developments
• 9.10. Zydus Lifesciences Limited
  • 9.10.1. Company Overview
  • 9.10.2. Key Executives
  • 9.10.3. Company Snapshot
  • 9.10.4. Operating Business Segments
  • 9.10.5. Product Portfolio
  • 9.10.6. Business Performance
  • 9.10.7. Key Strategic Moves and Developments

관련자료